Detail akcie Annovis Bio Rg-AI online

Business Summary: Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Annovis Bio Inc revenues was not reported. Net loss increased 2% to $19M. Higher net loss reflects Change in fair value of warrants decrease of 85% to $438K (income), Research and development - Balancing val increase of 12% to $15.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.52 to -$1.01.